M. Darsow

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer

S. Shak, F. Baehner, N. Harbeck, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast-Conserving Treatment of Breast Cancer – Oncological and Reconstructive Aspects

M. Rezai, R. Kimmig, S. Kümmel, 2008, Gynäkologisch-geburtshilfliche Rundschau.

Autologous and Alloplastic Breast Reconstruction – Overview of Techniques, Indications and Results

M. Rezai, S. Kümmel, S. Krämer, 2008, Gynäkologisch-geburtshilfliche Rundschau.

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

S. Shak, F. Baehner, N. Harbeck, 2020, Therapeutic advances in medical oncology.

Tumor-Adapted Reduction Mammoplasty in Oncoplastic Breast Surgery

M. Rezai, M. Darsow, 2007, Breast Care.

Focal Topic: Surgery of Breast Carcinoma

M. Rezai, R. Kimmig, S. Kümmel, 2008 .

Long-Term Morbidity Following Axillary Dissection in Breast Cancer Patients – Clinical Assessment, Significance for Life Quality and the Impact of Demographic, Oncologic and Therapeutic Factors

R. Kreienberg, T. Kuehn, M. Darsow, 2000, Breast Cancer Research and Treatment.

Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial

M. Hauptmann, S. Shak, N. Harbeck, 2021 .

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.

O. Gluz, S. Kuemmel, R. Kates, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.